Livforsakringsbolaget Skandia Omsesidigt Has $283,000 Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Livforsakringsbolaget Skandia Omsesidigt boosted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 74.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 840 shares of the medical equipment provider’s stock after purchasing an additional 359 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Intuitive Surgical were worth $283,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. GraniteShares Advisors LLC acquired a new stake in shares of Intuitive Surgical in the fourth quarter worth about $1,210,000. Everence Capital Management Inc. increased its stake in shares of Intuitive Surgical by 2.3% in the fourth quarter. Everence Capital Management Inc. now owns 9,930 shares of the medical equipment provider’s stock worth $3,350,000 after purchasing an additional 220 shares during the period. Main Street Research LLC increased its stake in shares of Intuitive Surgical by 96.6% in the fourth quarter. Main Street Research LLC now owns 73,132 shares of the medical equipment provider’s stock worth $24,672,000 after purchasing an additional 35,935 shares during the period. Guerra Pan Advisors LLC increased its stake in shares of Intuitive Surgical by 10.7% in the fourth quarter. Guerra Pan Advisors LLC now owns 897 shares of the medical equipment provider’s stock worth $303,000 after purchasing an additional 87 shares during the period. Finally, DGS Capital Management LLC increased its stake in shares of Intuitive Surgical by 20.8% in the fourth quarter. DGS Capital Management LLC now owns 867 shares of the medical equipment provider’s stock worth $292,000 after purchasing an additional 149 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG traded down $3.47 on Thursday, hitting $370.70. The company’s stock had a trading volume of 218,001 shares, compared to its average volume of 1,615,457. The company has a market capitalization of $131.39 billion, a PE ratio of 74.39, a PEG ratio of 5.88 and a beta of 1.36. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The company has a 50 day moving average price of $387.56 and a 200 day moving average price of $342.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 EPS for the quarter, topping the consensus estimate of $1.48 by $0.12. The business had revenue of $1.93 billion for the quarter, compared to the consensus estimate of $1.89 billion. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. Intuitive Surgical’s revenue was up 16.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.91 EPS. On average, equities analysts forecast that Intuitive Surgical, Inc. will post 4.93 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on ISRG shares. Raymond James lifted their price objective on Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Barclays lifted their price objective on Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Stifel Nicolaus lifted their price objective on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Piper Sandler boosted their price target on Intuitive Surgical from $325.00 to $425.00 and gave the company an “overweight” rating in a research note on Wednesday, January 24th. Finally, Truist Financial boosted their price target on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $375.70.

Insiders Place Their Bets

In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the transaction, the vice president now owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction on Friday, January 26th. The stock was sold at an average price of $370.20, for a total value of $740,400.00. Following the transaction, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,373,093.80. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Marshall Mohr sold 108,790 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the transaction, the vice president now directly owns 26,877 shares in the company, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. In the last quarter, insiders have sold 248,418 shares of company stock valued at $95,927,097. 0.90% of the stock is currently owned by corporate insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.